TransMedics Group, Inc. — Director's Dealing 2023

Feb 28, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: TransMedics Group, Inc. (TMDX)
CIK: 0001756262
Period of Report: 2023-02-23

Reporting Person: Hassanein Waleed H (Director, President & CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-02-23	Common Stock	S	6200	$70.31	Disposed	420244	Direct
2023-02-23	Common Stock	S	4807	$71.32	Disposed	415437	Direct
2023-02-23	Common Stock	S	3577	$73.43	Disposed	411860	Direct
2023-02-23	Common Stock	S	3243	$74.52	Disposed	408617	Direct
2023-02-23	Common Stock	S	20000	$75.15	Disposed	388617	Direct

Footnotes

F1: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan.

F2: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $70.00 to $70.85, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F3: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $71.00 to $71.63, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F4: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $73.10 to $73.93, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F5: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $74.00 to $74.90, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F6: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $75.00 to $75.50, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F7: Includes 37,332 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock.